Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Optinose Inc (OPTN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 584,500
  • Shares Outstanding, K 41,220
  • Annual Sales, $ 0 K
  • Annual Income, $ -48,900 K
  • 36-Month Beta N/A
  • Price/Sales 656.04
  • Price/Cash Flow N/A
  • Price/Book 3.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.75
  • Number of Estimates 2
  • High Estimate -0.71
  • Low Estimate -0.78
  • Prior Year -4.23
  • Growth Rate Est. (year over year) +82.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.51 +10.31%
on 08/14/18
27.51 -49.85%
on 07/18/18
-12.82 (-48.16%)
since 07/17/18
3-Month
12.51 +10.31%
on 08/14/18
30.00 -54.00%
on 07/09/18
-10.22 (-42.55%)
since 05/17/18
52-Week
12.51 +10.31%
on 08/14/18
30.00 -54.00%
on 07/09/18
-5.20 (-27.37%)
since 10/13/17

Most Recent Stories

More News
INVESTOR ALERT: Investigation of OptiNose Announced by Holzer & Holzer

Holzer & Holzer, LLC is investigating whether OptiNose, Inc. ("OptiNose" or the "Company") (NASDAQ: OPTN) complied with the federal securities laws. On August 14, 2018, OptiNose issued financial...

OPTN : 13.80 (-2.68%)
Optinose Reports Second Quarter 2018 Financial Results and Recent Operational Highlights

Company reports second quarter net product sales of $1.3 million and that more than 2,600 physicians have prescribed XHANCE since launch

OPTN : 13.80 (-2.68%)
Optinose to Report Second Quarter 2018 Financial Results and Corporate Updates on August 14, 2018

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the second...

OPTN : 13.80 (-2.68%)
Option Care Announces Expansion into Louisiana

Option Care Enterprises, Inc. ("Option Care"), the nation's largest provider of home and alternate treatment site infusion therapy services, is expanding patient access to care with...

OPTN : 13.80 (-2.68%)
Optinose Named a 2018 Best Place to Work by Philadelphia Business Journal

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has been named one of the Philadelphia...

OPTN : 13.80 (-2.68%)
Optinose Announces Publication of Pivotal Efficacy and Long-Term Safety Data for XHANCE in Peer Reviewed Journals

NAVIGATE II: XHANCE produced significant improvement in both co-primary outcome measures, congestion/obstruction at week four and total polyp grade at week 16

OPTN : 13.80 (-2.68%)
Optinose CEO Peter Miller and President and COO Ramy Mahmoud Named EY Life Sciences Entrepreneur Of The Year 2018 in Greater

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that CEO Peter Miller and President and Chief Operating...

OPTN : 13.80 (-2.68%)
Optinose Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Common Shares

OptiNose, Inc. (NASDAQ:OPTN), announced today the closing of its underwritten public offering of 5,750,000 of its common shares at a price to the public of $22.25 per common share, including 750,000 common...

OPTN : 13.80 (-2.68%)
Optinose Announces Pricing of Public Offering of Common Stock

OptiNose, Inc. (NASDAQ:OPTN), announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $22.25 per share, before underwriting...

OPTN : 13.80 (-2.68%)
Optinose Announces Launch of Public Offering of Common Stock

OptiNose, Inc. (NASDAQ:OPTN), announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) and commenced a proposed underwritten public...

OPTN : 13.80 (-2.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade OPTN with:

Business Summary

OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company's lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and...

See More

Key Turning Points

2nd Resistance Point 15.59
1st Resistance Point 14.70
Last Price 13.80
1st Support Level 13.18
2nd Support Level 12.55

See More

52-Week High 30.00
Fibonacci 61.8% 23.32
Fibonacci 50% 21.26
Fibonacci 38.2% 19.19
Last Price 13.80
52-Week Low 12.51

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar